Genomind
Business Services · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2200 Renaissance Blvd Ste 100, King Of P...Phone Number
(877) 895-8658Website
www.genomind.comRevenue
$29.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
3
1
1
About Genomind
Genomind is a pharmacogenetic testing laboratory specializing in personalized medicine in the field of psychiatry, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients' lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research.Explore more
Genomind Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Genomind your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Genomind has new funding data
Congratulate Masked Content for being promoted to Masked Content at Genomind
Click to see if Genomind had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Genomind has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Genomind recently announced quarterly report
Check out if Genomind is spiking on competitors!
Genomind, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Genomind launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Genomind
Find 2 more new buyers
Compare Similar Companies to Genomind
Compare insights from companies similar to Genomind, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Genomind
$29.5M
51-200
Private
$92.2M
2009
ZC
Zia ChoudhrySenior Vice President, Chief Marketing Officer
Company Profile Activity
Activity Insights
Genomind is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Genomind is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Genomind.
Genomind financials insights
Gather financial insights about Genomind, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$20.9M
Other Financing Round
$5M
2015
Private Equity
$6M
2016
Other Financing Round
$17.9M
2017
Series B
$31.9M
2020
Multiple Rounds
$10.4M
Genomind Tech Stack
A closer look at the technologies used by Genomind
Most Recent Scoops
Person-Based
Search, Medical Research, Pharmaceuticals, Healthcare Technology
Person-Based
Person-Based
Left Company
Executive Move
Executive Moves, Left Company
Funding
Project
Award, Spending/Investment
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Genomind
Sign Up For FreeTo access detailed company insights
Genomind is a pharmacogenetic testing laboratory specializing in personalized medicine in the field of psychiatry, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that im... Read More
